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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of educational and behavioural interventions for vitamin K antagonist anticoagulant therapy in patients with AF.
B A C K G R O U N D
Description of the condition
Atrial Fibrillation (AF) is the most common arrhythmia in clinical
practice (Fuster 2006) and is associated with a five-fold greater
risk of stroke and thromboembolism (Wolf 1991). Prevalence of
AF increases with age (Kannel 1998), from 1.5% at age 50-59
years to 23.5% at age 80-89 years (Wolf 1998), as does the in-
cidence of stroke attributable to AF (Lip 2006a). The lifetime
risk of developing AF is approximately one in four among people
aged 40 years and older (Lloyd-Jones 2007). Assessment of throm-
boembolic risk determines subsequent treatment plans. There are
many stroke risk-stratification models (Stroke Risk in AFWorking
Group 2007), derived from pooled analysis from the data of an-
tithrombotic treatment trials. The models vary in complexity, but
four key clinical features are consistently identified as independent
risk factors for stroke: prior stroke or TIA, older age (≥ 75), hyper-
tension, and diabetes mellitus. The CHADS2 (Gage 2001) stroke
risk stratification scheme is simple and well validated scheme, and
is the most widely employed. The acronym CHADS2 stands for
each of the risk factors: congestive heart failure, hypertension, aged
≥ 75 years, diabetes mellitus (for which one point is given for each
risk factor present), and previous stroke/TIA (which receives two
points). Thus the total score ranges from 0 to six. In the United
Kingdom, AF patients are risk stratified for stroke using the NICE
guidelines (NICE 2006). The NICE guidelines are a practical al-
gorithm based risk stratification. These evidence-based guidelines
stratify patients into low, moderate and high risk categories and
have similar predictive value for stroke and other vascular events
to the CHADS2 scheme (Lip 2006b).
Description of the intervention
Current guidelines (i.e. Fuster 2006; Gage 2001; Guyatt 2008;
NICE 2006) recommend antithrombotic therapy for all patients
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at high risk of stroke (CHADS2 ≥ 2), except for those with con-
traindications such as peptic ulcers, severe hypertension, bacterial
endocarditis, pregnancy, recent surgery (within one month), and
a history of intracerebral haemorrhage (NICE 2006). In a meta-
analysis, dose-adjustedwarfarin (within the InternationalNormal-
ized Ratio (INR) range of 2.0 to 3.0) significantly reduced the
risk of ischaemic stroke or embolism in patients with non-valvular
AF compared with both aspirin and placebo by 39% (CI, 22% to
52%) and 64% (CI, 41% to 62%), respectively (Hart 2007).
Whilst anticoagulant therapy dramatically reduces stroke risk, the
therapeutic range of the international normalised ratio (INR) is
narrow, and must be maintained. This can be problematic, with
INRs > 3.0 increasing the risk of major and minor bleeding and
INRs < 2.0 increasing the risk of thromboembolism (Lip 2006a).
Regular INRmonitoring is essential and patients need to carefully
adhere to dietary and lifestyle restrictions (Ansell 2004).
A recent retrospective analysis of anticoagulation in the UK
demonstrated that only patients with the greatest INR control in-
creased their time to stroke occurrence, with only patients spend-
ing > 71% of their time in target therapeutic range (TTR) ben-
efiting (Morgan 2009). In practice, 51% of patients at high risk
of stroke (CHADS2 ≥ 2) remained outside of their TTR for at
least 50% or more of the time (Morgan 2009). Further, a post
hoc analysis of patients enrolled in the Atrial Fibrillation Clopido-
grel Trial With Irbesartan for Prevention of Vascular Events (AC-
TIVE), which randomised AF patients with one additional stroke
risk factor to receive clopidogrel 75 mg/d plus aspirin (75 to 100
mg/d recommended) or oral anticoagulants (OACs), found that
patients with INRvalues that were within therapeutic range < 58%
of the time gained no benefit from anticoagulation treatment. The
INR must be with therapeutic range for ≥ 58% of the time to
confer benefit in terms of stroke risk reduction (Connolly 2008).
Thus, maintenance of INR is a major concern for both patients
and health care professionals.
Many factors can affect INR control such as non-adherence to
prescribed medication (Kumar 1989), inter-drug interactions and
variable dietary vitamin K intake (Holbrook 2005). Poor INR
control could also result from the patient’s limited knowledge of
their condition and their anticoagulant therapy, as several studies
have demonstrated poor knowledge of AF and its treatment (Lane
2006; Lip 2002; Nadar 2003; Tang 2003). Studies suggest that
knowledge of warfarin therapy correlates significantly with the
number of patientswith INRvalues in target range (Tang 2003). In
addition, there is an inverse relationship between age and patient
knowledge score (Tang 2003), suggesting that patients at highest
risk of stroke (aged 80 - 89 years) have the least understanding of
their condition and its treatment and are least likely to be within
therapeutic INR range (Tang 2003).
How the intervention might work
The use of OAC requires constant monitoring and thus may be
affected by numerous factors, including psychological and practi-
cal barriers to adherence. Behavioural and educational interven-
tions targeting patients receivingOACs for various conditions have
found a reduced incidence of major bleeding and mortality and
increased TTR compared to patients receiving usual care (Beyth
2000; Khan 2004). Beyth 2000 designed a randomised controlled
trial for all patients new to warfarin combining INR self monitor-
ing (using a portable monitor to check prothrombin time) and pa-
tient education. Throughout six months, the proportion of total
treatment time during which the INR was within the therapeu-
tic range was higher in the intervention group than in the usual
care group (56% vs. 32%; P < 0.001). Furthermore, major bleed-
ing was more common in the usual care group than the interven-
tion group (cumulative incidence, 12% vs. 5.6%, P < 0.05). In a
similarly designed RCT, Khan 2004 demonstrated that education
alone significantly increased TTR during the six months after the
intervention began. A brief educational intervention (Lane 2006)
specifically targeting AF patients found that whilst there was no
significant improvement in patient knowledge of the risks asso-
ciated with AF, the intervention significantly improved patient
knowledge about INR target range and the lifestyle factors that
affect INR levels (P = 0.001 and P = 0.014 respectively) (Lane
2006). Thus, educational interventions may have an important
role to play in optimising health outcomes for AF patients pre-
scribed treatment with warfarin.
Why it is important to do this review
Patients need sufficient information to make informed choices
and actively participate in the management of their own treat-
ment (Thrall 2004). Patient education aims to influence patient
behaviour and improve knowledge, attitudes and practices that
are necessary to improve health outcomes (Wofford 2008). Tech-
niques used in delivering patient education cover a wide spectrum
including the use of booklets and videos as media to transmit ad-
ditional information, alone or in addition to other self manage-
ment interventions (such as INR self monitoring) and interven-
tions which used decision aids. Behavioural interventions include
interventions that attempt to modify patients’ behaviour towards
treatment and symptoms such as cognitive behavioural therapy
(CBT), motivational interviewing and heart rate variability bio-
feedback. This reviewwill evaluate the value of educational and be-
havioural interventions for patients with AF, currently prescribed
warfarin. This review will evaluate the impact on the time spent
within the therapeutic INR range (TTR) and secondary outcomes
such as patient knowledge, quality of life. Psychological well being
and illness beliefs will also be evaluated.
O B J E C T I V E S
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To assess the effects of educational and behavioural interventions
for vitamin K antagonist anticoagulant therapy in patients with
AF.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) of any type of intervention
with any length of follow-up and in any language will be included.
Types of participants
Adults (aged 18 years or older) with AF (paroxysmal, persistent
or permanent), diagnosed and documented by electrocardiogram
(12-lead or Holter monitoring), who are eligible for, or currently
receiving vitamin K antagonist anticoagulant therapy will be con-
sidered eligible for inclusion in this review. Studies which include
AF patients with other medical conditions, will also be included in
this review where the studies are RCTs comparing at least one in-
tervention with a control group, and including patients with atrial
fibrillation as either the study population or a subgroup. Studies
will only be included where patients are grouped per indication
i.e. patients taking oral anticoagulants for AF, DVT/PE, valve re-
placements etc, and only AF patients data will be included within
the analysis.
Types of interventions
All types of educational and behavioural interventions given to AF
patients who were taking vitamin K antagonist anticoagulation
therapy will be considered for this systematic review. Educational
interventions include those giving patient information, such as us-
ing booklets and videos as media to transmit additional informa-
tion, alone or in addition to other self management interventions
(such as INR self monitoring), interventions which used decision
aids, and talking interventions. Behavioural interventions include
interventions that attempt to modify patients’ behaviour towards
treatment and symptoms such as cognitive behavioural therapy
(CBT), motivational interviewing and heart-rate variability bio-
feedback. Interventions could be targeted at adults on the indi-
vidual level or as a group intervention. The intervention may take
place in the emergency department, the hospital, the home or in
the community. The intervention could be delivered by a nurse,
pharmacist, educator, health or medical practitioner, or a multi-
disciplinary team associated with the hospital or referred to by the
hospital. The intervention could be undertaken at any time point
from diagnosis of AF or initiation of vitamin K antagonist therapy
(i.e. not only newly diagnosed AF patients or those newly referred
form anticoagulant therapy). Trials will only be considered where
the comparison groups are usual care, no intervention, or inter-
vention in combination with other self management techniques.
Usual care will be defined as standard anticoagulation clinic prac-
tice, where patients attend routine INR checks (defined as usual
care by the author). Any length of follow-up will be included.
Types of outcome measures
Primary outcomes
The primary outcomemeasure will be the percentage of time spent
within the therapeutic range (TTR), INR (2.0 to 3.0).
Secondary outcomes
The secondary outcomes will include:
• major bleeding (defined as bleeds that result in death, are
life threatening, cause chronic sequelae or consume major health
care resources) and minor bleeding (Schulman 2004);
• stroke and thromboembolic events;
• increased knowledge with regards to AFand anticoagulation
therapy;
• patient satisfaction;
• acceptability of the anticoagulant therapy;
• quality of life; psychological well being;
• changes in perception towards AF and INR control;
• changes in the patients’ illness beliefs and illness
representations;
• self reported adherence to treatment and a change in the
patients’ beliefs about medications;
• economic costs of the intervention (cost-effectiveness).
These outcomes may be quantified using validated or non-vali-
dated questionnaires, ratings or scales.
Search methods for identification of studies
Electronic searches
We will search the Cochrane Central Register of Controlled Tri-
als (CENTRAL) and the Database of Abstracts of Reviews of Ef-
fects (DARE) on The Cochrane Library, MEDLINE, EMBASE,
PsycINFO and CINAHL. See Appendix 1 for the search strategies
for The Cochrane Library and MEDLINE. These will be adapted
for use in the other databases.
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Searching other resources
Abstract books from national and international cardiology, psy-
chology and psychiatry conferences will be hand-searched. For ex-
ample:
• Society for Behavioural Medicine and the Division of
Health Psychology Conference
• European Health Psychology Conference
• Royal College of Psychiatrists Annual Meeting
Dissertation abstracts (UMI ProQuest Digital Dissertations) will
also be searched.
Reference lists of all relevant papers will be searched to identify
other potentially relevant articles. We will write to the lead author
of all relevant reports and to investigators interested in AF to see
if they know of any additional published or unpublished studies
that might be relevant to the review.
No language restrictions will be applied to these search strategies.
Data collection and analysis
Selection of studies
Two authors (Smith and Borg Xuereb) will scrutinise the titles
found from the search and decide on inclusion or exclusion. From
the included titles these two authors (Smith and Borg Xuereb)
will then select abstracts and papers for inclusion and exclusion.
Where disagreements arise on papers to include a third author will
make the decision on whether it meets the review criteria (Lane).
Data extraction and management
Two reviewers will independently extract the data. For each trial,
the following data will be extracted using a specially designed data
extraction form: participants (sample size, age, sex, ethnicity, mar-
ital status, type of Atrial Fibrillation); type of anticoagulation ther-
apy (warfarin, other); type and duration of the interventions (in-
tervention versus usual care or no intervention; other combina-
tions); primary and secondary outcomes (increase in knowledge
with regards to AFand anticoagulation therapy; time within the
therapeutic INR range; patient satisfaction; acceptability of the
anticoagulant therapy; quality of life; changes in perception to-
wards AF and INR control; changes in the patients’ illness beliefs
and illness representations; change in the patients’ beliefs about
medications; self reported adherence; psychological well being);
length of follow-up; statistical methods employed; the effect size
and its precision.
Assessment of risk of bias in included studies
Two reviewers will independently assess the methodological qual-
ity of each trial in accordance with guidelines in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins
2008). Each study will be assessed on several areas of bias (se-
quence generation, allocation concealment, degree of blinding,
particularly of the outcome assessors, patient attrition rate, selec-
tive reporting bias). The risk of bias will be determined using the
Collaboration’s risk of bias tool.
We will ask if the domains listed below are considered to be ade-
quate. There are three possible responses: Yes, No, or Unclear. Yes
indicates a low risk of bias and No indicates a high risk of bias. If
insufficient detail is reported the judgement on risk of bias will be
Unclear. The criteria for responses is outlined below:
Sequence generation
Yes, if the allocation sequence was generated using techniques such
as a random number table; a computer random number generator;
coin tossing; shuffling cards or envelopes; throwing dice.
No, if the allocation sequence was generated using techniques such
as odd or even date of birth; date (or day) of admission; hospital
or clinic record number.
Unclear, if there was insufficient information about the sequence
generation process to permit judgement.
Allocation concealment
Yes, if the allocation concealment used methods such as central
allocation (including telephone, web-based, and pharmacy-con-
trolled randomisation); sequentially numbered drug containers of
identical appearance; sequentially numbered opaque, sealed en-
velopes.
No, if the participants or investigators enrolling participants could
possibly foresee assignments and thus introduce selection bias such
as allocation based on using an open random allocation schedule
(e.g. a list of random numbers); assignment envelopes used with-
out appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque, or not sequentially numbered); alternation or rotation;
date of birth; case record number.
Unclear, if there was insufficient information to permit judgement
of Yes or No. If the method of concealment was not described or
not described in sufficient detail to allow a definite judgement (e.g.
if the use of assignment envelopes was described but it remained
unclear whether envelopes were sequentially numbered, opaque
and sealed).
Where the method of allocation is unclear, we plan to contact
study authors to provide further details.
Blinding
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Yes, if there was no blinding but the review authors judged that
the outcome and the outcome measurement was not likely to be
influenced by lack of blinding; if blinding of participants and key
study personnel was ensured and it was unlikely that the blinding
could have been broken; if either participants or some key study
personnel were not blinded but outcome assessment was blinded
and the non-blinding of others was unlikely to introduce bias.
No, if there was no blinding or incomplete blinding and the out-
come or outcome measurement was likely to be influenced by lack
of blinding; if blinding of key study participants and personnel
was attempted but it was likely that the blinding could have been
broken; if either participants or some key study personnel were
not blinded and the non-blinding of others was likely to introduce
bias.
Unclear, if there was insufficient information to permit judgement
of Yes or No or the study did not address this outcome (e.g. where
the blinding was described only as double-blind without any other
details).
Incomplete data assessment (loss of participants, for
example with withdrawals, dropouts, protocol deviations)
Yes, if there were no missing outcome data; reasons for missing
outcome data were unlikely to be related to the true outcome;
missing outcome data were balanced in numbers across interven-
tion groups with similar reasons for missing data across groups; for
dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk was not enough to have a clin-
ically relevant impact on the intervention effect estimate; for con-
tinuous outcome data, plausible effect size (difference in means or
standardised difference in means) among missing outcomes was
not enough to have a clinically relevant impact on observed effect
size; missing data were imputed using appropriate methods.
No, if the reasons for missing outcome data were likely to be re-
lated to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion of missing outcomes compared with
observed event riskwas enough to introduce clinically relevant bias
in the intervention effect estimate; for continuous outcome data,
plausible effect size (difference in means or standardised difference
in means) among missing outcomes was enough to introduce clin-
ically relevant bias in observed effect size; ‘as-treated’ analysis done
with substantial departure of the intervention received from that
assigned at randomisation; potentially inappropriate application
of simple imputation.
Unclear, if therewas insufficient reporting of attrition or exclusions
to permit judgement of Yes or No (e.g. numbers randomised were
not stated, no reasons for missing data were provided); or the study
did not address this.
Selective outcome reporting
Yes, if the study protocol was available and all of the study’s pre-
specified (primary and secondary) outcomes that were of interest
in the review were reported in the pre-specified way; the study
protocol was not available but it was clear that the published re-
ports included all expected outcomes, including those that were
pre-specified.
No, if not all of the study’s pre-specified primary outcomes were
reported; one ormore primary outcomeswere reported usingmea-
surements, analysis methods or subsets of the data (e.g. subscales)
that were not pre-specified; one or more reported primary out-
comes were not pre-specified (unless clear justification for their
reporting was provided, such as an unexpected adverse effect); one
or more outcomes of interest in the review were reported incom-
pletely so that they could not be entered in a meta-analysis; the
study report failed to include results for a key outcome that would
be expected to have been reported for such a study.
Unclear, if there was insufficient information to permit judgement
of Yes or No.
Other sources of bias
Yes, if the study appeared to be free of other sources of bias.
No, if there was at least one important risk of bias (e.g. the study
had a potential source of bias related to the specific study design
used; stopped early due to somedata-dependent process (including
a formal-stopping rule); had extreme baseline imbalance; had been
claimed to be fraudulent; had some other problem).
Unclear, if there was either insufficient information to assess
whether an important risk of bias existed or if there was insufficient
rationale or evidence that an identified problem would introduce
bias.
Measures of treatment effect
Statistical analysis would be undertaken as follows: for continu-
ous variables (e.g. changes in illness perception questionnaire or
changes in time spent within INR therapeutic range), the weighted
mean difference would be used. As a summary measure of effec-
tiveness, odds ratios with 95% confidence intervals will be calcu-
lated for dichotomous variables and where possible, the number
needed to treat (NNT) statistic would also be calculated.
Dealing with missing data
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We will try to contact the authors for studies with incomplete
information in published articles and for data clarifications if re-
quired. Investigators of unpublished trials will also be contacted.
Assessment of heterogeneity
Where relevant RCTs are identified assessment of their hetero-
geneity will be carried out. The I2 statistic will be examined to
describe the proportion of the variability in the results that is due
to heterogeneity. In addition, Chi-squared test for heterogeneity
will be performed and data will be considered heterogenous if P <
0.10. If significant heterogeneity is detected, possible explanations
will be looked for such as differences in population, the interven-
tion, setting and outcomes assessed.
Assessment of reporting biases
Publication bias will be tested by funnel plot based on the data
for the primary outcome of time spent within therapeutic INR
range. Asymmetry of the funnel plot will be taken as an indication
of publication bias. Other causes of asymmetry of funnel plot will
also be looked at like clinical heterogeneity between studies (for
example different control event rates) or methodological hetero-
geneity between studies (for example failure to conceal allocation).
A summary of who was blinded during both the conduct and
analysis of the study will also be summarised and conclusions will
inform the risk-of-bias tool. The completeness of the data will be
summarised and any concerns over the exclusion of participants
and/or excessive drop-out will be reported. Concerns over the
selective reporting of outcomes, time-points or sub-groups will
also be reported.
Data synthesis
Results of individual studies will initially be combined within a
narrative review. This will take into account methodological qual-
ity of the study. Where possible and appropriate, meta-analysis
will be used to statistically combine results. We will calculate the
percentage change (i.e. the per cent improvement relative to the
post intervention average in the control group). If insufficient data
are present to conduct a meta-analysis, we will report effect sizes
and confidence intervals (CIs) of the included studies using a stan-
dard method of presentation. TTR data will only be included if
directly reported, where available from personal communication
with the authors, or if all INR results for each participant for the
duration of the trial are available to permit calculation of TTR
using the Rosendaal method (Rosendaal 1993).
Subgroup analysis and investigation of heterogeneity
Subgroup analyses will be carried out looking at the type of inter-
vention (educational alone, behavioural alone, and a combination
of education and behavioural vs. usual care), frequency (one ses-
sion vs. multiple sessions) and duration (< 6 months / > 6months)
of the intervention, length of time on OAC, men vs. women, in-
dividual vs. group interventions and age of participant groups, de-
pendant upon the availability of such data in the included study
reports.
Sensitivity analysis
Sensitivity analyses would be employed to examine factors that
may lead to differences between the results of individual trials:
poor quality versus good quality trials.
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A P P E N D I C E S
Appendix 1. Search strategy
The Cochrane Library
#1 MeSH descriptor patient education as topic this term only
#2 MeSH descriptor attitude to health explode all trees
#3 MeSH descriptor patient participation this term only
#4 MeSH descriptor behavior therapy this term only
#5 MeSH descriptor cognitive therapy this term only
#6 MeSH descriptor counseling explode all trees
#7 MeSH descriptor motivation this term only
#8 MeSH descriptor goals this term only
#9 MeSH descriptor Biofeedback (Psychology) this term only
#10 MeSH descriptor decision support techniques this term only
#11 MeSH descriptor Communications Media explode all trees
#12 education in All Text
#13 (training in All Text or train in All Text)
#14 (teaching in All Text or teach in All Text)
#15 (behaviour* in All Text or behavior* in All Text)
#16 “patient knowledge” in All Text
#17 counsel* in All Text
#18 (cognitiv* in All Text near/3 therapy in All Text)
#19 (cognitiv* in All Text near/3 intervention* in All Text)
#20 motivation* in All Text
#21 contingency next management in All Text
#22 (biofeedback in All Text or bio-feedback in All Text)
#23 (goal in All Text or goals in All Text)
#24 (decision* in All Text near/3 aid* in All Text)
#25 pamphlet* in All Text
#26 booklet* in All Text
#27 video* in All Text
#28 decision next aid* in All Text
#29 “patient participation” in All Text
#30 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10)
#31 (#11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20)
#32 (#21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29)
#33 (#30 or #31 or #32)
#34 MeSH descriptor warfarin this term only
#35 MeSH descriptor Coumarins explode all trees
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#36 MeSH descriptor anticoagulants this term only
#37 MeSH descriptor vitamin k explode all trees with qualifiers: AI
#38 oral next anticoagula* in All Text
#39 Oral next anti-coagula* in All Text
#40 (“vitamin K” in All Text and (antagonist* in All Text or inhibitor* in All Text) )
#41 “antivitamin K” in All Text
#42 “anti-vitamin K” in All Text
#43 warfarin in All Text
#44 acenocoumarol in All Text
#45 sintrom in All Text
#46 sinthrome in All Text
#47 jantoven in All Text
#48 marevan in All Text
#49 coumadin* in All Text
#50 waran in All Text
#51 phenprocoumon in All Text
#52 nicoumalone in All Text
#53 VKA in All Text
#54 coumarin* in All Text
#55 dicoumarol in All Text
#56 dicumarol in All Text
#57 (#34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43)
#58 (#44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56)
#59 (#57 or #58)
#60 (#33 and #59)
MEDLINE on Ovid
1. Warfarin/
2. acenocoumarol/
3. Coumarins/
4. Phenindione/
5. Dicumarol/
6. Anticoagulants/
7. oral anticoagula$.tw.
8. exp Vitamin K/ai [Antagonists & Inhibitors]
9. warfarin.tw.
10. acenocoumarol.tw.
11. sintrom.tw.
12. sinthrome.tw.
13. jantoven.tw.
14. marevan.tw.
15. coumadin$.tw.
16. waran.tw.
17. Phenprocoumon/
18. nicoumalone.tw.
19. (vitamin k adj3 antagonist$).tw.
20. vitamin k inhibitor$.tw.
21. oral anticoagula$.tw.
22. oral anti-coagula$.tw.
23. vka.tw.
24. antivitamin k.tw.
25. anti-vitamin k.tw.
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26. or/1-25
27. Patient Education as Topic/
28. exp Attitude to Health/
29. Patient Participation/
30. ((educat$ or train$ or teach$) adj3 (program$ or intervention$)).tw.
31. (patient$ adj3 (train$ or teach$ or educat$ or inform$)).tw.
32. patient knowledge.tw.
33. Behavior Therapy/
34. Cognitive Therapy/
35. exp counseling/
36. (behavi$ adj3 (therap$ or manage$ or modif$ or chang$ or intervention$)).tw.
37. (cogniti$ adj3 (therap$ or intervention$)).tw.
38. counsel$.tw.
39. Motivation/
40. motivational interview$.tw.
41. contingency management.tw.
42. biofeedback.tw.
43. bio-feedback.tw.
44. goals/
45. (goal$ adj3 set$).tw.
46. decision support techniques/
47. decision$ aid$.tw.
48. exp communications media/
49. pamphlet$.tw.
50. booklet$.tw.
51. video$.tw.
52. or/27-51
53. 26 and 52
54. randomized controlled trial.pt.
55. controlled clinical trial.pt.
56. randomized.ab.
57. placebo.ab.
58. clinical trials as topic.sh.
59. randomly.ab.
60. trial.ti.
61. 54 or 55 or 56 or 57 or 58 or 59 or 60
62. exp animals/ not humans.sh.
63. 61 not 62
64. 53 and 63
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C O N T R I B U T I O N S O F A U T H O R S
Data collection, paper searches, screening and appraisal as well as data extraction will all be carried out by Smith and Borg Xuereb. Dr
Lane will advise on extraction method, analysis and general review processes. Interpretation of analysis and final drafts of the review
will be overseen by all of the authors.
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